The endothelial biology of sickle cell disease: Inflammation and a chronic vasculopathy

Microcirculation

Volumn 11, Issue 2, 2004, Pages 129-151

  Hebbel, Robert P ^a   Osarogiagbon, Raymond ^b   Kaul, Dhananjay ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Veterans Administration Center   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Endothelium; Inflammation; Sickle; Vascular

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; CD36 ANTIGEN; CELL ADHESION MOLECULE; GLYCOPROTEIN IB; HEMOGLOBIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; NITRIC OXIDE DONOR; PADGEM PROTEIN; POLOXAMER; POLYSACCHARIDE; SALAZOSULFAPYRIDINE; THROMBOSPONDIN; TICLOPIDINE; TUMOR NECROSIS FACTOR RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; VITRONECTIN RECEPTOR; WARFARIN;

AMINO ACID SUBSTITUTION; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; DISEASE COURSE; ERYTHROCYTE ADHESIVENESS; GENETIC DIFFERENCE; HUMAN; INFLAMMATION; LEUKOCYTE ADHERENCE; LUNG EDEMA; MOLECULAR MECHANICS; MOYAMOYA DISEASE; PATHOPHYSIOLOGY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REPERFUSION INJURY; RETINOPATHY; REVIEW; SICKLE CELL ANEMIA; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ANEMIA, SICKLE CELL; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; ERYTHROCYTES, ABNORMAL; GENOTYPE; HUMANS; INFLAMMATION; LEUKOCYTES; REPERFUSION INJURY; VASCULAR DISEASES;

EID: 3242792093     PISSN: 10739688     EISSN: None     Source Type: Journal    
DOI: 10.1080/10739680490278402     Document Type: Review

References (201)

1. Abboud M, Laver J, Blau CA. (1998). Granulocytosis causing sickle-cell crisis. Lancet 351 (9107):959.
2. Abu-Soud HM, Khassawneh MY, Sohn JT, Murray P, Haxhiu MA, Hazen SL. (2001). Peroxidases inhibit nitric oxide (NO) dependent bronchodilation: development of a model describing NO-peroxidase interactions. Biochemistry 40:11866-11875.
3. Adams-Graves P, Kedar A, Koshy M, Steinberg M, Veith R, Ward D, Crawford R, Edwards S, Bustrack J, Emanuele M. (1997). RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood 90:2041-2046.
4. Adedeji MO, Cespedes J, Allen K, Subramony C. Hughson MD. (2001). Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med 125:1436-1441.
5. Adler BK, Salzman DE, Carabasi MH, Vaughan WP, Reddy VV, Prehal JT. (2001). Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 97:3313-3314.
6. Adragna NC, Fonseca P, Lauf PK. (1994). Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. Blood 83:553-560.
7. Akinola NO, Stevens SME, Franklin IM, Nash GB, Stuart J. (1992). Subclinical ischaemic episodes during the steady state of sickle cell anaemia. J Clin Pathol 45:902-906.
8. Albelda SM, Buck CA. (1990). Integrins and other cell adhesion molecules. FASEB J 4:2868-2880.
9. Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA, Tousson A, Gladwin MT, Patel RP, Tarpey MM, Batinic-Haberle I, White CR, Freeman BA. (2001). Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 98:152115-15220.
10. Aslan M, Ryan TM, Townes TM, Coward L, Kirk MC, Barnes S, Alexander CB, Rosenfeld SS, Freeman BA. (2003). Nitric oxide-dependent generation of reactive species in sickle cell disease: actin tyrosine nitration induces defective cytoskeletal polymerization. J Biol Chem 278:4194-4204.
11. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. (1992). Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr 120:360-366.
12. Barabino GA, McIntire LV, Eskin SG, Sears DA, Udden M. (1987). Endothelial cell interactions with sickle cell, sickle trait, mechanically injured, and normal erythrocytes under controlled flow. Blood 70:152-157.
13. Barabino GA, Wise RJ, Woodbury VA, Zhang B, Bridges KA, Hebbel RP, Lawler J, Ewenstein BM. (1997). Inhibition of sickle erythrocyte adhesion to immobilized thrombospondin by von Willebrand factor under dynamic flow conditions. Blood 89:2560-2567.
14. Barabino GA, Liu XD, Ewenstein BM, Kaul DK. (1999). Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result in improved hemodynamic behavior. Blood 93:1422-1429.
15. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. (2000). Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vasoocclusion. Blood 96:2451-2459.
16. Belcher JD, Bryant CJ, Nguyen J, Bowlin PR, Kielbik MC, Bischof JC, Hebbel RP, Vercellotti GM. (2003). Transgenic sickle mice have vascular inflammation. Blood 101:3953-3959.
17. 2 production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood 99:2297-2303.
18. Bernini JC, Rogers ZR, Sandler ES, Reisch JS, Quinn CT, Buchanan GR. (1998). Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 92:3082-3089.
19. Boggs DR, Hyde F, Srodes C. (1973). An unusual pattern of neutrophil kinetics in sickle cell anemia. Blood 41:59-65.
20. Bridges KR, Barabino GD, Brugnara C, Cho MR, Christoph GW, Dover G, Ewenstein BM, Golan DE, Guttmann CR, Hofrichter J, Mulkern RV, Zhang B, Eaton WA. (1996). A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood 88:4701-4710.
21. Brittain HA, Eckman JR, Wick TM. (1992). Sickle erythrocyte adherence to large vessel and microvascular endothelium under physiologic flow is qualitatively different. J Lab Clin Med 120:538-545.
22. Brittain HA, Eckman JR, Swerlick RA, Howard RJ, Wick TM. (1993). Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vasoocclusion. Blood 81:2137-2143.
23. Brittain JE, Mlinar KJ, Anderson CS, Orringer EP, Parise LV. (2001). Activation of sickle red blood cell adhesion via integrin-associated protein/CD47-induced signal transduction. J Clin Invest 107:1555-1562.
24. Brittain JE, Mlinar KJ, Anderson CS, Orringer EP, Parise LV. (2001). Integrin-associated protein is an adhesion receptor on sickle red blood cells for immobilized thrombospondin. Blood 97:2159-2164.
25. Browne PV, Mosher DF, Steinberg MH, Hebbel RP. (1996). Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol 51:296-301.
26. Browne PV, Hebbel RP. (1996). CD36-positive stress reticulocytosis in sickle cell anemia. J Lab Clin Med 127:340-347.
27. Cabannes R, Lonsdorfer J, Castaigne JP, Ondo A, Plassard A, Zohoun I. (1984). Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. Agents Actions Suppl 15:199-212.
28. Cao J, Mathews MK, McLeod DS, Merges C, Hjelmeland LM. Lutty GA. (1999). Angiogenic factors in human proliferative sickle cell retinopathy. Br J Ophthalmol 83:838-846.
29. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, Vera JC, Levy PS. (1994). The acute chest syndrome in sickle cell disease: Incidence and risk factors. Blood 84:643-649.
30. Castro O, Hoque M, Brown BD. (2003). Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 101:1257-1261.
31. Chaplin H, Jr., Monroe MC, Malecek AC, Morgan LK, Michael J, Murphy WA. (1989). Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr Med J 66:574-584.
32. Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP. (1996). Hydroxyurea and sickle cell anemia: clinical utility of a myelosuppressive "switching" agent. The multicenter study of hydroxyurea in sickle cell anemia. Medicine 75:300-326.
33. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt A-M, Stern DM. (1998). Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91:3527-3561.
34. Closse C, Dachary-Prigent J, Boisseau MR. (1999). Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol 107:300-302.
35. Cokic VP, Smith RD, Beleslin-Cokic BB, Njoroge JM, Miller JL, Gladwin MT, Schechter AN. (2003). Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 111:231-239.
36. De Caterina R, Libby P, Peng H-B, Thannickal VJ, Rajavashisth TB, Gimbrone MAJ, Shin WS, Liao JK. (1995). Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 96:60-68.
37. de Chadarevian J-P, Balarezo FS, Heggere M, Dampier C. (2001). Splenic arteries and veins in pediatric sickle cell disease. Pediatr Dev Pathol 4:538-544.
38. de Jong K, Larkin SK, Styles LA, Bookchin RM, Kuypers FA. (2001). Characterization of the phosphatidylserine-exposing subpopulation of sickle cells. Blood 98:860-867.
39. Decastel M, Leborgne-Samuel Y, Alexandre L, Merault G, Berchel C. (1999). Morphological features of the human umbilical vein in normal, sickle cell trait, and sickle cell disease pregnancies. Hum Pathol 30:13-20.
40. Duits AJ, Pieters RC, Saleh AW, van Rosmalen E, Katerberg H, Berend K, Rojer RA. (1996). Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol 81:96-98.
41. Embury SH, Hebbel RP, Steinberg MH. Mohandas N. (1944). Sickle cell disease: basic principles and clinical practice. New York: Raven.
42. Embury SH, Hebbel RP, Steinberg MH, Mohandas N. (1994). Pathogenesis of vasoocclusion. In: Sickle Cell Disease: Basic Principles and Clinical Practice (SH Embury, RP Hebbel, N Mohandas, and MH Steinberg, Eds.) New York: Raven. 311-326.
43. Embury SH. (2004). The not-so-simple process of sickle cell vasoocclusion. Microcirculation 11:101-113.
44. Fabry ME, Fine E, Rajanayagam V, Factor SM, Gore J, Sylla M, Nagel RL. (1992). Demonstration of endothelial adhesion of sickle cells in vivo: a distinct role for deformable sickle cell discocytes. Blood 79:1602-1611.
45. Fadlon E, Vordermeier S, Pearson TC, Mire-Sluis AR, Dumonde DC, Phillips J, Fishlock K, Alun Brown K. (1998). Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood 91:266-274.
46. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RAB, Henson PM. (2000). A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 405:85-90.
47. Febbraio M, Hajjar DP, Silverstein RL. (2001). CD36: a class of B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 108:785-791.
48. Ferrone FA. (2004). Physiologic sickle hemoglobin polymerization. Microcirculation xx:xxx-xxx.
49. Fiorucci S, Mencarelli A, Meneguzzi A, Lechi A, Morelli A, del Soldata P, Minuz P. (2002). NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide. Circulation 106:3120-3125.
50. Francis RB, Jr., Hebbel RP. (1994). Hemostasis. In: Sickle Cell Disease: Basic Principles and Clinical Practice (SH Embury, RP Hebbel, MH Steinberg, and N Mohandas, Eds.) New York: Raven. 299-310.
51. Frazier WA. (1987). Thrombospondin: a modular adhesive glycoprotein of platelets and nucleated cells. J Cell Biol 105:625-632.
52. Frenette PS. (2004). Sickle cell vasoocclusion: heterotypic, multicellular, aggregations driven by leukocyte adhesion. Microcirculation 11:167-177.
53. Frishman WH, Ismail A. (2002). Role of infection in atherosclerosis and coronary artery disease: a new therapeutic target? Cardio Rev 10:199-210.
54. Gabay C, Kushner I. (1999). Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-454.
55. Garcia JGN, Pavalko FM, Patterson CE. (1995). Vascular endothelial cell activation and permeability responses to thrombin. Blood Coagul Fibrinolysis 6:609-626.
56. Gewaltig MT, Kojda G. (2002). Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res 55:250-260.
57. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S, Group ftNP-ES. (2003). Natalizumab for active Crohn's disease. N Eng J Med 348:24-32.
58. Gladwin MT, Schechter AN, Ognibene FP, Coles WA, Reiter CD, Schenke WH, Csako G, Waclawiw MA, Panza JA, Cannon RO III. (2003). Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 107:271-278.
59. Graido-Gonzalez E, Doherty JC, Bergreen EW, Organ G, Telfer M, McMillen MA. (1998). Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vasoocclusive sickle crisis. Blood 92:2551-2555.
60. Granger DN, Korthuis RJ. (1998). Physiologic mechanisms of postischemic tissue injury. Annu Rev Physiol 1995:311-332.
61. Greenberg J, Ohene-Frempong K, Halus J, Way C, Schwartz E. (1983). Trial of low doses of aspirin as prophylaxis in sickle cell disease. J Pediatr 102:781-784.
62. Griffin TC, McIntire D, Buchanan GR. (1994). High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 330:733-737.
63. Grisham MB, Granger DN, Lefer DJ. (1998). Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: Relevance to ischemic heart disease. Free Radic Biol Med 25:404-433.
64. Gupta K, Gupta P, Solovey A, Hebbel RP. (1999). Mechanism of interaction of thrombospondin with human endothelium and inhibition of sickle erythrocyte adhesion to human endothelial cells by heparin. Biochim Biophys Acta 1453:63-73.
65. Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP. (1999). Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 3:147-158.
66. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law P-Y, Yee D, Hebbel RP. (2002). Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 62:4491-4498.
67. Hammerman SI, Kourembanas S, Conca TJ, Tucci M, Brauer M, Farber HW.(1997). Endothelin-1 production during the acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 156:280-285.
68. Haque AK, Gokhale S, Rampy BA, Adegboyega P, Duarte A, Saldana MJ. (2002). Pulmonary hypertension in sickle cell hemoglobinopathy: a clinico-pathologic study of 20 cases. Hum Pathol 33:1037-1043.
69. Harada H, Pavlick KP, Hines IN, Lefer DJ, Hoffman JM, Bharwani S, Wolf RE, Grisham MB. (2003). Sexual dimorphism in reduced-size liver ischemia and reperfusion injury in mice: role of endothelial cell nitric oxide synthase. Proc Natl Acad Sci USA 100:739-744.
70. Hasen HB, Raines SL. (1962). Priapism associated with sickle cell disease. J Urol 88:71-76.
71. Hebbel RP, Boogaerts MAB, Eaton JW, Steinberg MH. (1980). Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med 302:992-995.
72. Hebbel RP, Yamada O, Moldow CF, Jacob HS. White JG. (1980). Abnormal adherence of sickle erythrocytes to cultured vascular endothelium. Possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest 65:154-160.
73. Hebbel RP, Moldow CF, Steinberg MH. (1981). Modulation of erythrocyte-endothelial interactions and the vasocclusive severity of sickling disorders. Blood 58:947-952.
74. Hebbel RP, Visser MR, Goodman JL, Jacob HS, Vercellotti GM. (1987). Potentiated adherence of sickle erythrocytes to endothelium infected by virus. J Clin Invest 86:1503-1506.
75. Hebbel RP, Ney PA, Foker W. (1989). Autoxidation, dehydration, and adhesivity may be related abnormalities of sickle erythrocytes. Am J Physiol 256:C579-C583.
76. Hebbel RP, Mohandas N. (1994). Sickle cell adherence. In: Sickle Cell Disease: Basic Principles and Clinical Practice (SH Embury, RP Hebbel, MH Steinberg, and N Mohandas, Eds.) New York: Raven. 217-239.
77. Hebbel RP. (1997). Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 99:2561-2564.
78. Hillery CA, Du MC, Montgomery RR, Scott JP. (1996). Increased adhesion of erythrocytes to components of the extracellular matrix: Isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin. Blood 87:4879-4886.
79. Hillery CA, Scott JP, Du MC. (1999). The carboxyterminal cell-binding domain of thrombospondin is essential for sickle red blood cell adhesion. Blood 94:302-309.
80. Hillery CA, Du MC, Wang WC, Scott JP. (2000). Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol 109:322-327.
81. Hillery CA, Panepinto JA. (2004). Pathophysiology of stroke in sickle cell disease. Microcirculation 11:195-208.
82. Hines PC, Zen Q, Burney SN, Shea D, Ataga KI, Orringer EP, Telen MJ, Parise LV. (2003). Novel epinephrine and cyclic AMP-mediated activation of BCAW/Lu-dependent sickle (SS) RBC adhesion. Blood 101:3281-3287.
83. Hofstra TC, Kalra VK, Meiselman HJ, Coates TD. (1996). Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst. Blood 87:4440-4447.
84. Hoover R, Rubin R, Wise G, Warren R. (1979). Adhesion of normal and sickle erythrocytes to endothelial monolayer cultures. Blood 54:872-877.
85. Huang J, Sommers EM, Kim-Shapiro DB, King SB. (2002). Horseradish peroxidase catalyzed nitric oxide formation from hydroxyurea. J Am Chem Soc 124:3473-3480.
86. Inwald DP, Kirkham FJ, Peters MJ, Lane R, Wade A, Evans JR, Klein NJ. (2000). Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia. Br J Haematol 111:474-481.
87. Joneckis CC, Ackley RL, Orringer EP, Wayner EA, Parise LV. (1993). Integrin α4β1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood 82:3548-3555.
88. Joneckis CC, Shock DD, Cunningham ML, Orringer EP, Parise LV. (1996). Glycoprotein IV-independent adhesion of sickle red blood cells to immobilized thrombospondin under flow conditions. Blood 87:4862-4870.
89. Joyce M, Kelly C, Winter D, Chen G, Leahy A, Bouchier-Hayes D. (2001). Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inbibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res 101:79-84.
90. Kalinowski L, Dobrucki LW, Brovkovych V, Malinski T. (2002). Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 105:933-938.
91. Kaul DK, Fabry ME, Nagel RL. (1986). Vasoocclusion by sickle cells: evidence for selective trapping of dense red cells. Blood 68:1162-1166.
92. Kaul DK, Fabry ME, Nagel RL. (1989). Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. Proc Nat Acad Sci USA 86:3350-3360.
93. Kaul DK, Nagel RL, Chen D, Tsai HM. (1993). Sickle erythocyte-endothelial interactions in microcirculation: the role of von Willebrand factor and implications for vasoocclusion. Blood 81:2429-2438.
94. Kaul DK, Chen D, Zhan J. (1994). Adhesion of sickle cells to vascular endothelium is critically dependent on changes in density and shape of the cells. Blood 83:3006-3017.
95. Kaul DK, Fabry ME, Constantini F, Rubin EM, Nagel RL. (1995). In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest 96:2845-2853.
96. Kaul DK, Hebbel RP. (2000). Hypoxia/ reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest 106:411-420.
97. Kaul DK, Tsai HM, Liu XD, Nakada MT, Nagel RL, Coller BS. (2000). Monoclonal antibodies to alpha V-beta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood 95:368-374.
98. Kaul DK, Liu X-d, Bryant C, Belcher JD, Vercellotti GM, Hebbel RP. (2002). Anti-inflammatory therapy ameliorates endothelial activation and improves microvascular blood flow in transgenic sickle mice. Blood 100 (suppl):44a.
99. Kaul DK, Hebbel RP. (2002). Inhibition of hypoxia/reoxygenation-induced inflammatory response and flow abnormalities in transgenic mice by anti-oxidant. therapy. Experimental Biology Meeting Abstracts:A85.
100. Kaul DK, Fabry ME. (2004). In vivo studies of sickle red blood cells. Microcirculation 11:153-165.
101. Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, Kuypers FA, Bach RR. (1998). Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 91:4216-4223.
102. Khademi M, Marquis JR. (1973). Renal angiography in sickle-cell disease. Radiology 107:41-46.
103. Kinney TR, Sleeper LA, Wang WC, Zimmerman RA, Pegelow CH, Ohene-Frempong K, Wethers DL, Bello JA, Vichinsky EP, Moser FG, Gallagher DM, DeBaun MR, Plat OS, Miller ST. (1999). Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics 103:640-645.
104. Klug PP, Kaye N, Jensen WN. (1982). Endothelial cell and vascular damage in the sickle cell disorders. Blood Cells 8:175-184.
105. Koh KK. (2000). Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47:648-657.
106. Koshy M, Thomas C, Goodwin J. (1990). Vascular lesions in the central nervous system in sickle cell disease (neuropathology). J Assoc Acad Minority Phys 1:71-78.
107. Koshy M, Burd L. (1994). Obstetric and gynecologic issues. In: Sickle Cell Disease: Basic Principles and Clinical Practice (SH Embury, RP Hebbel, MH Steinberg, and N Mohandas, Eds.) New York: Raven. 689-702.
108. Kubo-Inoue M, Egashira K, Usui M, Takemoto M, Ohitani K, Katoh M, Shimokawa H, Takeshita A. (2002). Long-term inhibition of nitric oxide synthesis increases arterial thrombogenecity in rat carotid artery. Am J Physiol Heart Circ Physiol 282:H1478-H1484.
109. Kumar A, Eckman JR, Swerlick RA, Wick TM. (1996). Phorbol ester stimulation increases sickle erythrocyte adherence to endothelium: A novel pathway involving alpha 4 beta 1 integrin receptors on sickle reticulocytes and fibronectin. Blood 88:4348-4358.
110. Kumar A, Eckman JR, Wick TM. (1996). Inhibition of plasma-mediated adherence of sickle erythrocytes to microvascular endothelium by conformationally constrained RGD-containing peptides. Am J Hematol 53:92-98.
111. Kurantsin-Mills J, Ofosu FA, Safa TK, Siegel RS, Lessin LS. (1992). Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients. Br J Haematol 81:539-544.
112. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. (2003). Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111: 1201-1209.
113. Lard LR, Mul FP, de Haas M, Roos D, Duits AJ. (1999). Neutrophil activation in sickle cell disease. J Leukoc Biol 66:411-415.
114. Laufs U, Gertz K, Dirnagl U, Böhm M, Nickenig G, Endres M. (2002). Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 942:23-30.
115. Lee SP, Cunningham ML, Hines PC, Joneckis CC, Orringer EP, Parise LV. (1998). Sickle cell adhesion to laminin: potential role for the alpha5 chain. Blood 92:2951-2958.
116. Lee K, Gane P, Roudot-Thoraval F, Godeau B, Bachir D, Bernaudin F, Cartron J-P, Galacteros F, Bierling P. (2001). The nonexpression of CD36 On reticulocytes and mature red blood cells does not modify the clinical course of patients with sickle cell anemia. Blood 98:966-971.
117. Libby P. (2002). Inflammation in atherosclerosis. Nature 420:868-874.
118. Lutty GA, Goldberg MF. (1994). Ophthalmologic complications. In: Sickle Cell Disease: Basic Principles and Clinical Practice (SH Embury, RP Hebbel, N Mohandas, and MH Steinberg, Eds.) New York: Raven.
119. Lutty GA, Taomoto M, Cao J, McLeod DS, Vanderslice P, McIntyre BW, Fabry ME, Nagel RL. (2001). Inhibition of TNF-alpha-induced sickle RBC retention in retina by a VLA-4 antagonist. Invest Ophthalmol Vis Sci 42:1349-1355.
120. Manodori AB, Barabino GA, Lubin BH, Kuypers FA. (2000). Adherence of phosphatidylserine-exposing erythrocytes to endothelial matrix thrombospondin. Blood 96:1293-1300.
121. Matsui NM, Borsig L, Rosen SD, Yaghmai M, Varki A, Embury SH. (2001). P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood 98:1955-1962.
122. Matsui NM, Varki A, Embury SH. (2002). Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood 100:3790-3796.
123. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, Wethers DL, Smith J, Kinney TR. (2000). Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 342:1612-1613.
124. Mohandas N, Evans E. (1985). Sickle erythrocyte adherence to vascular endothelium: morphologic correlates and the requirement for divalent cations and collagen-binding plasma proteins. J Clin Invest 76:1605-1612.
125. Mohandas N, Ballas SK. (1994). Erythrocyte density and heterogeneity. In: Sickle Cell Disease: Basic Principles and Clinical Practice (SH Embury, RP Hebbel, N Mohandas, and MH Steinberg, Eds.) New York: Raven.
126. Montes RAO, Eckman JR, Hsu LL, Wick TM. (2002). Sickle erythrocyte adherence to endothelium at low shear: role of shear stress in propagation of vasoocclusion. Am J Hematol 70:216-227.
127. Mosseri M, Bartlett-Pandite AN, Wene K, Isner JM, Weinstein R. (1993). Inhibition of endothelium-dependent vasorelaxation by sickle erythrocytes. Am Heart J 126:338-346.
128. Natarajan M, Udden MM, McIntire LV. (1996). Adhesion of sickle red blood cells and damage to interleukin-1beta stimulated endothelial cells under flow in vitro. Blood 87:4845-4852.
129. Nath KA, Grande JP, Haggard JJ, Croatt AJ, Katusic ZS, Solovey A, Hebbel RP. (2001). Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol 158:893-903.
130. Nath KA, Katusic ZS, Gladwin MT. (2004).The perfusion paradox and vascular instability in sickle cell disease. Microcirculation 11:179-193.
131. Navab M, Fogelman AM, Berliner JA, Territo MC, Demer LL, Frank JS, Watson AD, Edwards PA, Lusis AJ. (1995). Pathogenesis of atherosclerosis.Am J Cardiol 76:18C-23C.
132. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM. (1998). Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 91:288-294.
133. Orringer EP, Casella JF, Ataga KI, Koshy M, Adams-Graves P, Luchtman-Jones L, Wun T, Watanabe M, Shafer F, Kutlar A, Abboud M, Steinberg M, Adler B, Swerdlow P, Terregino C, Saccente S, Files B, Ballas S, Brown R, Wojtowicz-Praga S, Grindel JM. (2001). Purified poloxamer 188 for treatment of acute vasoocclusive crisis of sickle cell disease: a randomized controlled trial. JAMA 286:2152-2153.
134. Osarogiagbon UR, Choong S, Belcher JD, Vercellotti GM, Paller MS, Hebbel RP. (2000). Reperfusion injury pathophysiology in sickle transgenic mice. Blood 96:314-320.
135. Ou J, Ou Z, Jones DW, Holzhauer S, Hatoum OA, Ackerman AW, Weihrauch DW, Gutterman DD, Guice K, Oldham KT, Hillery CA, Pritchard KA Jr. (2003) L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 107:2337-2341.
136. Perelman N, Selvaraj SK, Batra S, Luck LR, Erdreich-Epstein A, Coates TD, Kalra JK, Malik P. (2003). Placenta growth factor activates monocytes and correlates with sickle cell disease severity. BLOOD 102:1506-1514.
137. Phelan M, Perrine SP, Brauer M, Faller DV. (1995). Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J Clin Invest 96:1145-1151.
138. Pieters RC, Rojer RA, Saleh AW, Saleh AEC, Duits AJ. (1995). Molgramostim to treat SS-sickle cell leg ulcers. Lancet 345:528-529.
139. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. (1994). Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 330:1639-1644.
140. Preissner KT, Nawroth PP, Kanse SM. (2000). Vascular protease receptors: Integrating haemostasis and endothelial cell functions. J Pathol 190:360-372.
141. Prengler M, Pavlakis SG, Prohovnik I, Adams RJ. (2002). Sickle cell disease: the neurological complications. Ann Neurol 51:543-552.
142. Reiter CD, Wang X, Tanus-Santos JE. Hogg N, Cannon ROI, Schechter AN, Gladwin MT. (2002). Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8:1383-1389.
143. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, Dammacco F. (1999). Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627-2636.
144. Rothman SM, Fulling KH, Nelson JS. (1986). Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann Neurol 20:684-690.
145. Saleh AW, Hillen HF, Duits AJ. (1999). Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol 102:31-37.
146. Salvaggio JE, Arnold CA, Banov CH. (1963). Long-term anticoagulation in sickle-cell disease: a clinical study. N Engl J Med 269:182-186.
147. Scallon B, Cai A, Solowski N, Rosenberg A, Song X-Y, Shealy D, Wagner C. (2002). Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418-426.
148. Scotborn DJ, Price C, Schwartz D, Terrill C, Buchanan GR, Shurney W, Sarniak I, Fallon R, Chu J-Y, Pegelow CH, Wang W, Casella JF, Resar LS, Berman B, Adamkiewicz T, Hsu LL, Ohene-Frempong K, Smith-Whitley K, Mahoney D, Scott JP, Woods GM, Watanabe M, DeBaun MR. (2002). Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr 140:348-354.
149. Setty BNY, Dampier CD, Stuart MJ. (1995). Arachidonic acid metabolites are involved in mediating red blood cell adherence to endothelium. J Lab Clin Med 125:608-617.
150. Setty BNY, Stuart MJ. (1996). Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Blood 88:2311-2320.
151. Setty BN, Chen D, Stuart MJ. (1996). Sickle red blood cells stimulate endothelial cell production of eicosanoids and diacylglycerol. J Lab Clin Med 128:313-321.
152. Setty BN, Rao AK, Stuart MJ. (2001). Thrombophilia in sickle cell disease: the red cell connection. Blood 98:3228-3233.
153. Setty BN, Kulkarni S, Dampier CD, Stuart MJ. (2001). Fetal hemoglobin in sickle cell anemia: relationship to erythrocyte adhesion markers and adhesion. Blood 97:2568-2573.
154. Setty BNY, Kulkarni S, Stuart MJ. (2002). Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. Blood 99:1564-1571.
155. Setty BNY, Stuart MJ. (2002). Eicosanoids in sickle cell disease: potential relevance of neutrophil leukotriene B4 to disease pathophysiology. J Lab Clin Med 139:80-89.
156. Shet A, Aras OA, Gupta K, Hass MJ, Rausch DJ, Saba N, Koopmeiners L, Key NS, Hebbel RP. (2003). Sickle blood contains tissue factor positive microparticles derived from endothelial cells and monocytes. Blood (in press).
157. Shiu YT, Udden MM, McIntire LV. (2000). Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood 95:3232-3241.
158. Shiu YT, McIntire LV, Udden MM. (2002). Sickle erythrocytes increase prostacyclin and endothelin-1 production by cultured human endothelial cells under flow conditions. Eur J Haematol 68:163-169.
159. Shweiki D, Itin A, Soffer D, Keshet E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845.
160. Silverstein RL. (1999). The vascular endothelium. In: Inflammation: Basic Principles and Clinical Correlates (JI Gallin and R Snyderman, Eds.) Philadelphia: Lippincott, Williams & Wilkins. 207-225.
161. Smith CM, Hebbel RP. Tukey DP, Clawson CC, White JG, Vercellotti GM. (1987). Pluronic F-68 reduces the endothelial adherence and improves the rheology of liganded sickle erythrocytes. Blood 69:1631-1636.
162. Smolinski PA, Offermann MK, Eckman JR, Wick TM. (1995). Double-stranded RNA induces sickle erythrocyte adherence to endothelium: a potential role for viral infection in vasoocclusive pain episodes in sickle cell anemia. Blood 85:2945-2950.
163. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. (1997). Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 337:1584-1590.
164. Solovey A, Gui L, Keys NS, Hebbel RP. (1998). Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest 101:1899-1904.
165. Solovey A, Gui L, Ramakrishnan S, Steinberg MH, Hebbel RP. (1999). Sickle cell anemia as a possible' state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. Blood 93:3824-3830.
166. Solovey AA, Solovey AN, Harkness J, Hebbel RP. (2001). Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 97:1937-1941.
167. Sowemimo-Coker SO, Haywood LJ, Meiselman HJ, Francis RB, Jr. (1992). Effects of normal and sickle erythrocytes on prostacyclin release by perfused human umbilical cord veins. Am J Hematol 40:276-282.
168. Space SL, Lane PA, Pickett CK, Weil JV. (2000). Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium. Am J Hematol 63:200-204.
169. Steinberg MH, Mohandas N. (1994). Laboratory values. In: Sickle Cell Disease: Basic Principles and Clinical Practice (SH Embury, RP Hebbel, N Mohandas. and MH Steinberg, Eds.) New York: Raven. 469-484.
170. Stone WL, Payne PH, Adebonojo FO. (1990). Plasma-vitamin E and low plasma lipoprotein levels in sickle cell anemia patients. J Asso Acad Minority Phys 1:12-16.
171. Stone PCW, Stuart J, Nash GB. (1996). Effects of density and of dehydration of sickle cells on their adhesion to cultured endothelial cells. Am J Hematol 52:135-143.
172. Stuart MJ, Yamaja Setty BN. (1999). Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood 94:1555-1560.
173. Styles LA, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, Kuypers F. (1997). Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 89:2554-2559.
174. 2 predicts impending acute chest syndrome in sickle cell disease. Blood 96:3276-3278.
175. Subbanagounder G, Wong JW, Lee H, Faull KF, Miller E, Witztum JL, Berliner JA. (2002). Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. J Biol Chem 277:7271-7281.
176. + sickle reticulocytes to endothelial cells. Blood 80:2634-2642.
177. Sultana C, Shen Y, Rattan V, Johnson C, Kalra VK. (1998). Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes. Blood 92:3924-3935.
178. Swerlick RA, Eckman JR, Kumar A, Jeitler M, Wick TM. (1993). Alpha 4 beta 1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium. Blood 82:1891-1899.
179. Tomer A, Harker LA, Kasey S, Eckman JR. (2001). Thrombogenesis in sickle cell disease. J Lab Clin Med 137:398-407.
180. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. (2002). Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci USA 99:3047-3051.
181. Udani M, Zen Q, Cottman M, Leonard N, Jefferson S, Daymont C, Truskey G, Telen MJ. (1998). Basal cell adhesion molecule/Lutheran protein: the receptor critical for sickle cell adhesion to laminin. J Clin Invest 101:2550-2558.
182. Veillard NR, Mach F. (2002). Statins: the new aspirin? Cell Molec Life Sci 59:1771-1786.
183. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, Nickerson B, Orringer E, McKie V, Bellevue R, Daeschner C, Manci EA. (2000). Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med 342:1855-1865.
184. Volin MV, Harlow LA, Woods JM, Campbell PL, Amin MA, Tokuhira M, Koch AE. (1999). Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicylic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis. Arthritis Rheum 42:1927-1935.
185. Vordermeier S, Singh S, Biggerstaff J, Harrison P, Grech H, Pearson TC, Dumonde DC, Brown KA. (1992). Red blood cells from patients with sickle cell disease exhibit an increased adherence to cultured endothelium pretreated with tumour necrosis factor (TNF). Br J Hematol 81:591-597.
186. Wahl C, Liptay S, Adler G, Schmid RM. (1998). Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101:1163-1174.
187. Wan JG, Mu JS, Zhu HS, Geng JG. (2002). N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo. Inflamm Res 51:4315-443.
188. Wautier JL, Pintigny D, Wautier MP, Paton RC, Galacteros F, Passa P, Caen JR. (1983). Fibrinogen, a modulator of erythrocyte adhesion to vascular endothelium. J Lab Clin Med 101:911-920.
189. Wautier JL, Galacteros F, Wautier MP, Pintigny D, Beuzard Y, Rosa J, Caen JP. (1985). Clinical manifestations and erythrocyte adhesion to endothelium in sickle cell syndrome. Am J Hematol 19:121-130.
190. Wautier JL, Pintigny D, Maclouf J, Wautier MP, Corvazier E, Caen J. (1986). Release of prostacyclin after erythrocyte adhesion to cultured vascular endothelium. J Lab Clin Med 107:210-215.
191. + thalassemia. Blood 97:3998-3999.
192. Weinstein R, Zhou MA, Bartlett-Pandite A, Wenc K. (1990). Sickle erythrocytes inhibit human endothelial cell DNA synthesis. Blood 76:2146-2152.
193. Wick TM, Moake JL, Udden MM, Eskin SG, Sears DA, McIntire LV. (1987). Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow. J Clin Invest 80:905-910.
194. Wick TM, Moake JL, Udden MM, McIntire LV. (1993). Unusually large von Willebrand factor multimers preferentially promote young sickle and non-sickle erythrocyte adhesion to endothelial cells. Am J Hematol 42:284-292.
195. Wolters HJ, ten Cate H, Thomas LLM, Brandjes DPM, van der Ende A, van der Heide Y, van Eps LWS. (1995). Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: promises for treatment? Br J Haematol 90:715-717.
196. Wun T, Paglieroni T, Field CL, Welborn J, Cheung A, Walker NJ, Tablin F. (1999). Platelet-erythrocyte adhesion in sickle cell disease. J Invest Med 47:121-127.
197. Wun T, Cordoba M, Rangaswami A, Cheung AW, Paglieroni T. (2002). Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin Lab Haematol 24:81-88.
198. Xie L, Chesterman CN, Hogg PJ. (2001). Control of von Willebrand factor multimer size by thrombospondin-1. J Exp Med 193:1341-1349.
199. Yang Y, Loscalzo J. (2000). Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation 101:2144-2148.
200. Yipp BG, Anand S, Schollaardt T, Patel KD, Looareesuwan S, Ho M. (2000). Synergism of multiple adhesion molecules in mediating cytoadherence of Plasmodium falciparum-infected erythrocytes to microvascular endothelial cells under flow. Blood 96:2292-2298.
201. Zhang R, Brennan ML, Shen Z, MacPherson JC, Schmitt D, Molenda CE, Hazen SL. (2002). Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem 277:46116-46122.